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Abstract 
Purpose: To determine if implementation of revised pain medication administration guidelines 
in PACU led to improved patient satisfaction scores, lower pain scores at discharge from PACU, 
lower pain medication and antiemetic medication costs in PACU, and shorter average PACU 
length-of-stay (LOS) at the clinical site. 
Background and Significance: Negative consequences of poorly managed acute postoperative 
pain include diminished function and quality of life, compromised surgical recovery, extended 
use of opioids, development of chronic postoperative pain, and increased morbidity and medical 
costs (Gan, 2017). There is an impetus to minimize narcotic medications administered after 
surgery, while still providing adequate pain management in the acute postoperative period.  
Intervention and Implementation Plan: The revised pain medication administration guidelines 
were implemented March 1, 2017. The following data points were compared to evaluate impact: 
PACU LOS, patient satisfaction scores, PACU discharge pain scores, and costs for antiemetics 
and oral (PO) and IV pain medications. Pre-implementation data includes a three-month sample 
from 2016. Post-implementation data includes three-month samples in 2017, 2018, 2019, and 
2020. PACU nurses were surveyed in January 2021. 
Project Outcomes: Patients who received only PO and/or IV pain medications in PACU had: 
average LOS decrease 8%, IV narcotic costs decrease 5%, analgesic costs decrease 2%, 
discharge pain scores increase 12%, and antiemetic costs increase 68%. Nurses’ perceptions of 
the guidelines on their practice and patient outcomes were positive, and patient satisfaction 
scores were stable.  
Keywords: PACU, guidelines, medication costs, pain scores, length-of-stay, satisfaction 
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Using Revised Pain Medication Administration Guidelines in Post Anesthesia Care Unit 
(PACU): A Program Evaluation 
Purpose of the Evaluation 
The purpose of this program evaluation is to determine if implementation of revised pain 
medication administration guidelines in PACU led to improved patient satisfaction scores, lower 
pain scores at discharge from PACU, lower medication costs, fewer rescue antiemetics being 
administered, and shorter PACU lengths-of-stay at the clinical site. 
Origins and Goals of Effort  
A level-one trauma center’s surgical services department post-anesthesia care unit 
(PACU) revised the pain medication administration clinical guidelines in response to Det Norske 
Veritas Healthcare, Inc. (DNV) findings during a hospital accreditation survey. DNV is an 
approved Centers for Medicare and Medicaid Services (CMS) accreditor. The hospital was cited 
for improper ordering of medications leading to medication administration non-conformity in 
January of 2017. Pain medication orders lacked appropriate pain medication administration 
guidelines, which resulted in nurses choosing which pain medications to give and at what doses. 
This was a problem throughout the hospital, so revision of pain medication order sets became 
part of a hospital-wide initiative. The revision of pain medication administration guidelines for 
PACU was also necessary because the average PACU length-of-stay (LOS) was consistently 
longer than the national benchmark of two hours, and this was largely due to pain management 
issues and overreliance on IV narcotics to treat pain. Extended LOS in PACU negatively affected 
the operating room (OR) schedule. Monitoring patients in the OR once surgery was completed 
due to inability to transfer to PACU caused delays for the cases to follow, which resulted in 
frustrated patients, surgeons, and staff, and increased costs. The PACU nurse manager led the 
USING REVISED PAIN MEDICATION ADMINISTRATION  4 
change to revise the pain medication administration clinical guidelines for immediate 
postoperative adult patients in PACU, and the chief physician anesthesiologist authored the 
guideline revisions. The guidelines were revised to clarify which medications were to be given 
for “acute” pain or for “post-acute” pain while the patient was in PACU. The postoperative pain 
medication order sets in PACU were altered to include the revised guidelines in March 2017, but 
only LOS was evaluated, and a comprehensive evaluation was not performed to assess impact of 
the change. This author conducted a formal program evaluation of the revised pain medication 
administration clinical guidelines as a DNP project.  
Target Population, Activities, and Services  
The population for this program evaluation was immediate postoperative adult patients in 
PACU at one clinical site, an urban level-one trauma center in a city in Hennepin County in the 
Minneapolis-St. Paul metropolitan area in the state of Minnesota. The county is large, covering 
approximately 610 square miles. Hennepin County is home to the city of Minneapolis, and forty-
four other cities (Your Government, Overview: Learn About the County, 2020). Minnesota’s 
population in 2018 was 5,519,952, and the population of Hennepin County was 1,232,483 (The 
University of Wisconsin Population Health Institute, 2019). Hennepin County is part of a seven-
county metropolitan area (Wright & Roesler, 2019). Detailed demographic information for 
Hennepin County and the state of Minnesota, adapted from the County Health Rankings and 
Roadmaps website, can be found in Appendix A. 
The PACU at the clinical site recovered 10,302 patients in 2018 and 10,032 patients in 
2019. Parties affected by the quality improvement project included postoperative adult patients 
and the staff who provided direct patient care after surgery. The quality improvement project was 
implemented March 1 of 2017, and patient involvement started on admission to PACU from the 
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operating room after surgery and ended on discharge from the PACU. The reason for the quality 
improvement project was to not only meet DNV accreditation requirements, but also to reduce 
PACU LOS and provide effective treatment of postoperative pain through utilization of revised 
pain medication administration guidelines by PACU nursing staff, with the expectation of 
judicious administration of opioids and minimized reliance on IV opioids for postoperative pain 
control in the patient population.  
Review of Related Research 
Opioid Crisis and the Postoperative Pain Connection  
The opioid crisis in the United States has been a major focus of the Centers for Medicare 
and Medicaid Services (CMS), Centers for Disease Control and Prevention (CDC), and state and 
county health departments in recent years. According to the CDC (2011), 73.8% of deaths 
caused by prescription medication overdoses involved opioid pain relievers. Sale rates of opioids 
from 1999 to 2010, and overdose death rates from 1999 to 2008, both quadrupled. The treatment 
admission rate for substance abuse was almost six times higher in 2009 compared to 1999 
(Centers for Disease Control & Prevention, 2011).  According to the CDC website, there were 
over 17,000 opioid overdose deaths resulting from prescription opioids in the United States in 
2017. That is approximately 46 deaths per day, and the number is considered undercounted 
because deaths due to synthetic opioids other than methadone, as well as overdose deaths where 
the specific drug was not listed on the death certificate, are not included in the count. The reason 
synthetic opioid prescription pain medications such as fentanyl and tramadol were not counted is 
because the National Vital Statistics System (NVSS) does not distinguish between deaths caused 
by pharmaceutical fentanyl vs illegally manufactured fentanyl (IMF) or other synthetic opioids 
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that are pharmaceutical vs illegally manufactured (CDC's Response to the Opioid Overdose 
Epidemic, 2019). 
According to the CMS website and the Hospital Consumer Assessment of Healthcare 
Providers and Systems (HCAHPS) Fact Sheet, pain management was a measured outcome on 
HCAHPS surveys from October 2006 to December 2017, and HCAHPS scores were tied to 
payment from CMS starting in 2012 as part of the “Hospital Value-Based Purchasing program” 
(Centers for Medicare & Medicaid Services website, n.d.; "HCAHPS Fact Sheet," 2017). Pain 
management as a measured outcome on HCAHPS surveys followed by CMS payment being 
impacted by pain management satisfaction scores is thought to be one of the contributors to 
overprescribing of opioid pain relievers and increase in abuse of these medications. In response 
to the opioid epidemic, CMS replaced the pain management questions on the HCAHPS survey 
with questions that focused on communication about pain. This change affected surveys for 
patients discharged in January 2018 and beyond. Starting in October 2019, all pain 
communication questions were eliminated from the HCAHPS survey. Removal of these 
questions was intended to help CMS “comply with the requirements of the Substance Use-
Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and 
Communities Act” ("HCAHPS changes," 2018).  
The state of Minnesota is not immune to the opioid epidemic. The Minnesota Department 
of Health reported that non-fatal opioid overdoses resulted in 2,037 emergency room visits in 
2017, and 860 of those did not involve heroin. The number of people in 2014 admitted to the 
hospital for opioid use disorder was 304.3 per 100,000, and 736.3 per 100,000 were admitted to 
the hospital for treatment of chronic pain. The number of people admitted to treatment for opioid 
abuse in 2015 was 10,332 (Opioid Overdose Prevention, 2019). According to a report written by 
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Wright and Roesler (2019), drug overdose rates that involved opioids increased by 7% and 
overall drug overdose rates increased by 9% in the state of Minnesota from 2016 to 2017. The 
largest increase was seen in the seven-county Minneapolis-St. Paul metropolitan area, but there 
was also an increase noted in greater Minnesota. In one year, from 2016 to 2017, the statewide 
deaths that involved overdose of synthetic opioids such as fentanyl increased by 86%, while the 
overdoses involving heroin decreased 26%. In the seven-county metropolitan area over the same 
period, synthetic opioids were involved in 97% of opioid-involved deaths, and heroin overdose 
deaths decreased by 17%. In the metropolitan area and greater Minnesota in 2017, the age group 
with the greatest numbers of opioid overdose deaths were people 45-54 years old, and a higher 
proportion of males than females died from drug overdoses (males 62%, females 38%). Though 
the overall drug overdose mortality rate for Minnesota is among the lowest in the nation (44 out 
of 50), there are significant racial disparities. The state was ranked number one when measuring 
the disparity between African Americans and Caucasian people for overdose deaths. According 
to the authors of the report, the racial disparities have gotten worse. From 2015 to 2017, 
statewide drug overdose mortality rates for American Indians went from 47.3 to 76.2 per 
100,000 residents, and rates for African Americans increased from 20.8 to 27.6 per 100,000. In 
contrast, during the same 3 years, statewide drug overdose mortality rates for Caucasians 
increased from 10.1 to 12.1 per 100,000. The report did not separate prescription vs. illegal 
opioid overdose deaths (Wright & Roesler, 2019).   
Groups who are at greater risk of developing opioid use disorder are men, middle-aged 
adults, those living in rural areas, and Caucasians, American Indians, and Alaska Natives 
(Centers for Disease Control and Prevention [CDC], 2011). Opioid abuse can start with legal 
opioids prescribed for pain, and surgery can be a catalyst for the development of prescription 
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opioid abuse. A retrospective cohort study by Alam, Gomes, Zheng, Mamdani, Juurlink, and 
Bell (2012) concluded that older adult patients who were opioid naïve were 44% more likely to 
use opioids long-term within 1 year of short-stay surgery if they were prescribed an opioid 
within 7 days of surgery. The study included 391,139 opioid-naïve patients aged 66 or older who 
had cataract surgery, a laparoscopic cholecystectomy, a transurethral resection of the prostate 
(TURP), or varicose vein stripping surgery (Alam et al., 2012). According to a retrospective 
analysis of 641,941 opioid naïve surgical patients by Sun, Darnall, Baker, and Mackey (2016), 
chronic opioid use in the first year after surgery ranged from 0.119% up to 1.41%. Eleven 
surgical procedures were included in the study: functional endoscopic sinus surgery (FESS), 
cataract surgery, TURP, total knee arthroplasty (TKA), total hip arthroplasty (THA), open 
cholecystectomy, laparoscopic cholecystectomy, open appendectomy, laparoscopic 
appendectomy, cesarean delivery, and simple mastectomy. The surgery with the highest 
incidence of chronic opioid use in the first year was total knee arthroplasty. Total hip 
arthroplasty surgery was also listed as high risk for the development of chronic opioid use in the 
first year after surgery. The authors identified that those who were most vulnerable to the 
development of chronic opioid use were men, people older than age 50, and people with a 
preoperative history of depression, antidepressant use, benzodiazepine use, alcohol abuse, or 
drug abuse (Sun et al., 2016). All the surgical procedures included in the studies by Sun, Darnall, 
Baker, & Mackey (2016) and Alam, Gomes, Zheng, Mamdani, Juurlink, and Bell (2012) are 
performed at the clinical site where this program evaluation took place. Overreliance on opioids 
in the postoperative period can result in patients experiencing opioid-induced side effects, which 
require additional medications or interventions and can delay discharge from PACU in the short 
USING REVISED PAIN MEDICATION ADMINISTRATION  9 
term and can have larger implications related to the opioid epidemic, including an increase in 
abuse of prescription opioids. 
Multimodal Analgesia for Pain Management  
According to Gan (2017), inadequately managed acute postoperative pain affects a 
significant segment of postoperative patients.  Negative consequences of poorly managed acute 
postoperative pain include diminished function and quality of life, compromised surgical 
recovery, extended use of opioids, development of chronic postoperative pain, and increased 
morbidity and medical costs (Gan, 2017). It is crucial to ensure that pain will be managed 
effectively in the acute postoperative period. Opioids are commonly administered perioperatively 
and postoperatively. It may not always be possible to eliminate the administration of opioids, but 
there is an impetus to give as little narcotic as possible during and after the surgery, while still 
providing adequate pain management. Non-opioid pain medications are effective in reducing the 
need for opioid medications. Oral non-steroidal anti-inflammatory drugs (NSAIDS), both 
selective and non-selective, and oral or intravenous acetaminophen/paracetamol significantly 
reduced postoperative pain in several studies. The need for additional analgesia was significantly 
reduced with acetaminophen/paracetamol (Liang et al., 2017; Maund et al., 2011), COX-2 
inhibitors (Maund et al., 2011), and ibuprofen plus paracetamol (Derry et al., 2013).  Given 
together, acetaminophen and ibuprofen are more effective in the treatment of pain than when 
given alone (Derry et al., 2013). Celecoxib 400mg provided longer pain relief than non-selective 
NSAIDs and was as effective in relieving acute pain as ibuprofen 400mg (Derry & Moore, 
2013). Serious adverse events associated with oral analgesics were rare (1 in 3200), and were 
mainly seen with opioids, opioid combination drugs, and ibuprofen plus caffeine (Moore et al., 
2015). The need for rescue opioid pain medications was reduced when NSAIDs, acetaminophen, 
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or COX-2 inhibitors were used as part of a multimodal pain approach (Liang, et al., 2017; Derry, 
et al., 2013; Maund, et al., 2011). A literature synthesis table (Appendix B) includes details on 
each study. 
Multimodal analgesia is practiced by using more than one family of analgesic 
medications to target different receptors in the body, rather than just one type of receptor, to 
provide more comprehensive pain relief and minimize side effects. Multimodal analgesia also 
typically involves more than one route of medication administration to treat pain. An example of 
multimodal analgesia could include patient-controlled epidural analgesia with local anesthetic 
and opioid, scheduled oral acetaminophen, and IV opioids as needed for breakthrough pain. 
American Pain Society Guidelines (2016) were compared to UpToDate recommendations 
(2020), and both guidelines recommended multimodal approaches in the management of acute 
perioperative pain. These approaches included combinations of analgesic medications like 
NSAIDs, acetaminophen, COX-2 inhibitors, gabapentinoids, NMDA receptor antagonists, 
opioids, local anesthetics, as well as medications that are not meant to treat pain but have shown 
synergistic effects or may potentiate other pain medications. Recommendations for medications 
and routes of administration varied based on surgery type, length of time postoperative analgesia 
would be needed, patient history of opioid dependence, and whether the patient was taking 
buprenorphine or methadone preoperatively (Chou et al., 2016; Mariano et al., 2020). 
Multimodal analgesia is an effective approach to manage pain in surgical patients and can reduce 
the need for opioid analgesics. 
Overview and Description of the Program Evaluation 
The W.K. Kellogg Foundation’s (WKKF) Evaluation Guide (2017) steps are applied to 
this program evaluation project. Stakeholders are involved in all stages of the program evaluation 
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and are considered an important resource to the evaluator and the evaluation process. The 
WKKF guide for program evaluation has seven stages: A. preparation, B. determination of 
stakeholders and stakeholder engagement opportunities, C. identification of assumptions of what 
the results will be, D. development of a plan for evaluation, E. collection and analysis of data, F. 
communication of results and interpretation and facilitation of learning, G. use what was learned 
to determine next steps (W.K. Kellogg Foundation [WKKF], 2017). The overview and 
description of the program evaluation encompasses WKKF stages A-D. WKKF stage E is 
represented in the evaluation design, stage F in the evaluation results, and stage G in the 
summary, conclusion, and recommendations.  
Preparation  
 The most appropriate evaluation type for the improvement project is an outcome 
evaluation because the project was implemented in 2017 and no changes were made to the 
guidelines since implementation. The evaluation approach is mainly systems-oriented, as the 
project was implemented in a complex environment. Preoperative and intraoperative 
management could affect pain management and antiemetic requirements in PACU, and PACU 
nurses could choose to ignore the guidelines or make other care decisions unrelated to the project 
that effect a patient’s ability to meet discharge criteria. The methods utilized are primarily 
quantitative in nature, but some qualitative feedback was obtained from PACU nurses. Data 
captured during patients’ stays in PACU was collected from before the implementation of the 
guidelines and compared to data after the implementation. The qualitative and quantitative 
survey data from PACU nurses was obtained in January of 2021 after the guidelines had been 
implemented and utilized for approximately four calendar years. The DNP student was not an 
employee of the institution and served as an external evaluator. 
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Stakeholders 
The following stakeholders were identified: patients, PACU nurse manager, anesthesia 
department, PACU nurses, quality improvement (QI) department, pharmacy department, surgical 
services administration, financial department, surgeons, and the evaluator (DNP student). The 
PACU nurse manager and a nurse anesthetist served as clinical site preceptors for the evaluator 
and were consulted through each stage of the evaluation project and for data collection. Staff 
from the pharmacy department were consulted for data sources and data collection related to 
medications. The QI Department director was consulted to clarify the DNV citation specific to 
PACU and other details relevant to the QI project implementation. PACU nurses were consulted 
on their perceptions of the implementation, use, and impact of the revised pain medication 
administration guidelines on their practice and patient outcomes.  
Assumptions 
The initial theory of change for the project was that revised pain medication 
administration guidelines would meet DNV accreditation requirements and lead to a reduction of 
PACU length-of-stay. The expectation was that PACU nurses would have better guidance in 
determining which pain medications and doses were appropriate to give to patients. Additionally, 
pain would be managed, and side-effects would be minimized to allow patients to meet discharge 
criteria sooner. During reconstruction of the logic model with stakeholders after the guidelines 
had been implemented, it was determined that it may be beneficial to evaluate a broader set of 
outcomes beyond length-of stay and meeting accreditation requirements for medication orders. 
The logic model (Appendix C) includes the additional outcomes that were expected. 
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Evaluation Plan  
Three aims were developed for the program evaluation. The first aim was to evaluate the 
impact of the revised pain medication administration guidelines in PACU to determine if 
implementation led to improved patient satisfaction scores, lower pain scores at discharge from 
PACU, lower medication costs, fewer rescue antiemetics being administered, and shorter PACU 
length-of-stay (LOS). The objective to meet the first aim was to complete an outcome evaluation 
of the revised pain medication administration guidelines in PACU to determine the impact on 
patient satisfaction scores, discharge pain scores, medication costs, number of antiemetic doses 
administered, and LOS. The second aim was to evaluate baseline data on patient satisfaction 
scores, PACU discharge pain scores, medication costs, number of antiemetic doses administered, 
and PACU LOS prior to implementation of the revised pain medication administration 
guidelines. The objective to meet the second aim was to review patient satisfaction data that was 
obtained prior to implementation; complete a chart audit to determine baseline data on discharge 
pain scores, medication costs, number of antiemetic doses administered, and LOS prior to 
implementation of the revised pain medication administration guidelines. The third aim was to 
determine the perceptions of PACU nurses regarding the utility and impact of the revised pain 
medication administration guidelines on their practice and patient outcomes. The objective to 
meet the third aim was to solicit written feedback from PACU nurses regarding their perceptions 
on the utility and impact of the guidelines on their practice and patient outcomes. 
Evaluation questions were identified through discussion with stakeholders and review of 
the logic model objectives. The impact of the implementation of the revised pain medication 
administration guidelines in PACU on patients, PACU nurses, and the institution was evaluated 
by seeking answers for the following questions: 
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• Did PACU length-of-stay decrease after implementation? 
• Did PACU discharge pain scores change, or were they stable? 
• Did the cost of antiemetic medications or number of rescue antiemetic medications 
administered in PACU decrease after implementation? 
• Was there a change in overall PACU pain medication costs? 
• Was there an increase in oral pain medication costs? 
• Was there an increase in IV non-narcotic medication costs? 
• Was there a decrease in IV narcotic medication costs? 
• Did patient satisfaction survey scores change? 
• What were the perceptions of PACU nurses regarding the utility and impact of the 
guidelines on their practice and on patient outcomes?  
Evaluation Design 
Data Collection and Analysis 
The DNV citation occurred in January of 2017. Baseline aggregate data and patient 
satisfaction survey scores were acquired from a 3-month sample prior to the DNV site visit, from 
October 1 to December 31 of 2016. The quality improvement project was implemented March 1 
of 2017, and 90.4% of PACU nurses had completed education by April 1 of 2017. Post-
implementation data included three-month samples of aggregate data and patient satisfaction 
survey scores for the following date ranges: April 1 to June 30 of 2017, 2018, and 2019, as well 
as January 1 to March 31 of 2020. The decision was made to use January 1 to March 31 data for 
the year 2020 because COVID-19 restrictions, that started in mid to late March of 2020 and 
changed throughout 2020, affected surgical caseloads.  
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Quantitative data from patient medical records was obtained by the PACU nurse 
manager, a nurse anesthetist, and pharmacy staff using pre-existing reports in the electronic 
medical record system (EPIC). Report data was shared with this program evaluator as encrypted 
Excel files. The raw data from these reports was filtered to remove duplicate entries, pediatric 
patients (under age 18 at time of surgery), and patients who did not have a procedure in the OR 
and a subsequent PACU stay during the specified date ranges. Then each patient was assigned a 
case number. Duplicate medication administrations and medication administrations outside of 
each individual patient’s PACU stay were removed. Each medication administration was labeled 
with the proper assigned case number, then any remaining patient identifiers were removed. The 
removed patient identifiers included name, date of birth, medical record number, hospital 
account record, and PACU log number. Patients were then separated into three groups for 
comparison: patients who received only oral analgesics in PACU (PO group), patients who 
received only IV analgesics in PACU (IV group), and patients who received a combination of 
oral and IV analgesics in PACU (PO+IV group). Patients who received a combination of 
medications that included other routes of administration such as intra-muscular injections, 
epidural, or rectal were not included in the program evaluation. The data points compared were 
PACU LOS, PACU discharge pain scores, and PACU pain medication and rescue antiemetic 
medication costs.  
Patient satisfaction survey data was obtained by the PACU nurse manager as a Press 
Ganey report, which was sent to the evaluator in PDF format. The evaluator and stakeholders 
determined that the most relevant question from the patient satisfaction survey was: “Staff ensure 
you were comfortable". Scores for that question were extracted from the PDF report for the date 
ranges included in the program evaluation and entered in an Excel spreadsheet.  
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A written survey and letter of introduction (Appendix D) was emailed to a PACU nurse 
who volunteered to champion the PACU staff survey portion of the program evaluation. The 
PACU nurse then distributed the survey to the PACU nursing staff and collected the completed 
surveys in an envelope at the PACU nurses’ station. Participation was voluntary. The survey 
consisted of one yes/no question, fourteen questions on a Likert scale of 1-5, and six open-ended 
questions. Nurses who were working in PACU at the time of the initial implementation of the 
revised pain medication guidelines in March of 2017 were asked to complete the entire survey. 
Nurses who began working in PACU after March 1 of 2017 were asked to complete questions 
12-21. The staff was given three weeks in January of 2021 to complete the survey and place it in 
an envelope at the PACU nurses’ station. The program evaluator was then able to pick up the 
sealed envelope containing the completed surveys at the hospital’s front desk.  
Evaluation Results 
PACU Length-of-Stay 
 Baseline PACU LOS was determined by calculating the average LOS in minutes over the 
three-month period of October 1 to December 31, 2016 for each of the three groups. Post-
implementation PACU LOS for each of the three groups was determined by calculating the 
average LOS in minutes of the following date ranges: April 1 to June 30 of 2017, 2018, and 
2019; and January 1 to March 31 of 2020. The IV group had a 10-minute decrease, the PO group 
had a 23-minute increase, the PO+IV group had a 34-minute decrease, and the three groups 
combined had an overall decrease of 9 minutes in PACU LOS post-implementation (see Figure 1 
and Appendix F, Table F1). 
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Figure 1. 
 
Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474; 
PO+IV group 2016 n=16 and 2017-2020 average n=58 
 
PACU Discharge Pain Scores 
Baseline PACU discharge pain scores were determined by calculating the average 
discharge pain score over the three-month period of October 1 to December 31, 2016 for each of 
the three groups. Post-implementation PACU discharge pain scores for each of the three groups 
were determined by calculating the average discharge pain scores of the following date ranges: 
April 1 to June 30 of 2017, 2018, and 2019; and January 1 to March 31 of 2020. The IV group 
average discharge pain score increased from 3.3 to 3.8, the PO group increased from 2.7 to 2.9, 
and the PO+IV group decreased from 4.4 to 4.2 on a 0-10 pain scale post-implementation (see 




















PO Group 27% increase (23
minutes)
IV Group 9% decrease (10
minutes)
PO+IV Group 22% decrease
(34 minutes)
Overall (3 groups
combined) 8% decrease (9
minutes)
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Figure 2. 
 
Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474; 
PO+IV group 2016 n=16 and 2017-2020 average n=58 
 
Antiemetic Medication Costs 
To calculate antiemetic medication costs, first a single cost per dose was assigned to each 
antiemetic medication given in PACU. This cost per medication dose was determined by 
calculating the average cost charged to patients within the evaluation date ranges in 2016-2020 
for each antiemetic medication dose given in PACU (Appendix E). Baseline PACU antiemetic 
medication costs for the program evaluation were determined by calculating the sum of 
antiemetic medication doses and associated costs over the three-month period of October 1 to 
December 31, 2016 for each of the three groups. Post-implementation PACU antiemetic 
medication costs for each of the three groups were determined by calculating the average sum of 
antiemetic medication doses and associated costs for the following date ranges: April 1 to June 
30 of 2017, 2018, and 2019; and January 1 to March 31 of 2020. The IV group average 








PO Group (8% increase)
IV Group (15% increase)
PO+IV Group (4%
decrease)
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the PO+IV group increased $108.22 post-implementation. The overall antiemetic costs for the 
three groups combined increased 68% ($310.50) (Figure 3 and Appendix F, Table F3).  
Figure 3. 
 
Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474; 
PO+IV group 2016 n=16 and 2017-2020 average n=58 
 
Analgesic Medication Costs 
To calculate analgesic medication costs, first a single cost per dose was assigned to each 
analgesic medication given in PACU. This cost per medication dose was determined by 
calculating the average cost charged to patients within the evaluation date ranges in 2016-2020 
for each analgesic medication dose given in PACU (Appendix E). Baseline PACU analgesic 
medication costs for the program evaluation were determined by calculating the sum of analgesic 
medication doses and associated costs over the three-month period of October 1 to December 31, 
2016 for each of the three groups. Post-implementation PACU analgesic medication costs for 



















3 groups combined 68%
increase ($310.50)
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doses and associated costs for the following date ranges: April 1 to June 30 of 2017, 2018, and 
2019; and January 1 to March 31 of 2020. The IV group average analgesic medication costs 
decreased by $8,205.05 (12%), the PO group costs increased by $426.18 (243%), and the PO+IV 
group increased by $6,052.55 (212%) post-implementation. The analgesic costs for the three 
groups combined decreased by $1,169.55 (2%) (see Figure 4 and Appendix F, Table F4).  
Figure 4.  
 
Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474; 
PO+IV group 2016 n=16 and 2017-2020 average n=58 
 
Comparisons were also made by analgesic type and route of administration for the three 
groups combined. IV narcotic medication costs, excluding patient-controlled analgesia (PCA) 
doses, decreased by $2,450.67 (5%). Narcotic and non-narcotic total PO analgesic costs 
increased $987.67 (238%). IV non-narcotic analgesic costs increased $219.26 (1%) (see Figure 5 











Total Analgesic Costs by Group
PO Group 243% increase
($426.18)
IV Group 12% decrease
($8,205.05)
PO+IV Group 212% increase
($6052.55)
3 groups combined 2%
decrease ($1,169.55)




Patient Satisfaction Survey Scores 
Baseline patient satisfaction survey scores for the clinical site were determined by 
calculating the average percentage of each response for the question “Staff ensure you were 
comfortable” over the three-month period of October 1 to December 31, 2016. Post-
implementation patient satisfaction survey scores for the clinical site were determined by 
calculating the average percentage of each response for the question “Staff ensure you were 
comfortable” for the following date ranges: April 1 to June 30 of 2017, 2018, and 2019; and 
January 1 to March 31 of 2020. The average percentage of patients who answered “Yes, 
definitely” to the question “Staff ensure you were comfortable” remained stable, with a 0.24% 



























PACU Nurse Survey 
Written feedback was solicited from PACU nurses. Question 1 was a yes/no question 
asking if the nurse worked in PACU at the clinical site prior to March 1, 2017. Questions 2-15 
were answered using a 1-5 Likert scale. Questions 2-11 had fewer responses because the nurses 
who did not work in PACU until after the change was implemented were not able to answer 
those questions. Out of 28 total PACU nurses on staff, 16 nurses answered the survey; 7 worked 
in PACU prior to implementation of the revised pain medication administration guidelines, and 9 
started working in PACU after implementation. Most nurses found the guidelines to be practical 
and easy to use, they utilized them when deciding which medication to administer, and felt more 
confident in treating pain. Nurses who worked in PACU prior to the change in the guidelines all 
agreed that they gave more non-opioid medications, and most felt they gave less IV fentanyl and 
more IV hydromorphone. Most felt they were treating pain differently, patients seemed more 














2016 (Average n= 37) 2017-2020 (Average n= 65)









Out of the 16 completed nurse surveys, 11 nurses included open-ended feedback. Themes 
that were identified in those open-ended responses included patient outcomes, PACU LOS, 
PACU standing orders, effect on practice, and quality improvement opportunities. Nurses 
perceived shorter LOS, improved surgical thruput, improved outcomes, and happier patients with 
better and quicker pain control. They felt the PACU standing orders need more non-opioid 
options. PACU nurses also noted that variations in anesthesia providers’ intra-operative and 
post-operative management affects their ability to effectively treat pain with the current options 
in the standing orders. For the effect on their practice, nurses liked being able to use nursing 
judgement to treat pain and found the guidelines convenient and helpful in directing pain 
management. They also identified some opportunities for future quality improvement including a 
focus on pre-operative medications and the pre-operative patient environment, continuing with 

































-5 0 5 10 15 20
2.Treated post-operative pain differently
3. Guidelines improved patient care
4. Patients seemed more satisfied
5. Gave less IV fentanyl
6. Improved patient comfort
7. Gave more IV dilaudid
8. Changed the way I treated postoperative pain
9. Gave fewer IV opioid medications
10. Gave more oral pain medications
11. Gave more non-opioid pain medications
12. Helped me feel more confident in treating pain
13. Guidelines are practical
14. Utilize guidelines to help decide which medication to…
15. Guidelines are easy to use
Nurse Survey Likert Scale Results
Strongly disagree=5 Disagree=4 Neither=3 Agree=2 Strongly agree=1
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anesthesia providers’ pain management techniques intra-operatively and post-operatively (see 
Table 1). 
Table 1. 
PACU Nurse Survey Qualitative Feedback Summary 
Themes Summary of Answers 
Patient outcomes 
• Shortened LOS with better/quicker pain control 
• Improved outcomes 
• Happier patients with pain managed 
PACU LOS 
• Improved perception of surgical thruput 
• Shorter LOS 
• Decreased PACU recovery time 
PACU standing orders 
• Need more non-opioid options 
• Variation in anesthesia providers’ intra-operative and post-
operative management affects ability to effectively treat 
pain with current options 
Effect on practice 
• Use nursing judgement to treat pain 
• Convenient 
• Helps direct and manage pain 
Quality improvement 
opportunities 
• Pre-operative medications and pre-operative patient 
management (calming environment) 
• Continue with enhanced recovery after surgery (ERAS) 
protocols and non-opioids prior to surgery 
• More consistency between anesthesia provider pain 
management techniques intra-operatively and post-
operatively 
 
Summary, Conclusion, and Recommendations 
 Aim #1 was met: Evaluate the impact of the revised pain medication administration 
guidelines in PACU to determine if implementation led to improved patient satisfaction scores, 
lower pain scores at discharge from PACU, lower medication costs, fewer rescue antiemetics 
being administered, and shorter PACU length-of-stay (LOS). Aim #2 was met: Establish baseline 
data on patient satisfaction scores, PACU discharge pain scores, medication costs, number of 
antiemetic doses administered, and PACU LOS prior to implementation of the revised pain 
medication administration guidelines. Overall PACU LOS decreased by 9 minutes (8%) and 
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discharge pain scores increased 12%, from 3.3 to 3.7 on a 0-10 pain scale. Average IV opioid 
costs decreased by $2,450.67 (5%), and average oral analgesic costs and IV non-narcotic 
analgesic costs increased $1,206.94 (6%). Antiemetic doses and the associated costs increased by 
68% ($310.50) for the three groups combined. Despite the changes in pain scores and 
medications being given, patient satisfaction scores were stable, with a 0.24% increase. 
The low number of antiemetic doses administered in PACU before and after 
implementation likely influenced the outcome. In addition to the low overall numbers of 
antiemetics given, the need for antiemetics may be impacted by multiple factors such as surgical 
procedure performed, patient age and sex, and anesthetic technique used. The numbers of cases 
in the PO group (2016 n=10 and 2017-2020 average n=43) and PO+IV group (2016 n=16 and 
2017-2020 average n=58) were low. The changes in PACU LOS, PACU discharge pain scores, 
medication costs, and antiemetic doses administered for the PO group and PO+IV group could 
be due to the low number of cases in those groups.  
Aim #3 was met: Determine the perceptions of PACU nurses regarding the utility and 
impact of the revised pain medication administration guidelines on their practice and on patient 
outcomes. Nurses perceived that they gave more IV hydromorphone (Dilaudid), more non-opioid 
medications, and less IV fentanyl. They also perceived having happier patients, improved 
outcomes, and quicker, better pain control for patients as well as shorter PACU stays and 
improved surgical thruput. PACU nurses felt the guidelines were practical, convenient, and easy 
to use. They also felt more confident in treating pain and liked using nursing judgement to treat 
pain. 
Results of the program evaluation will be shared with clinical site stakeholders and could 
be used as evidence to accreditors and hospital administration of ongoing evaluation. I 
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recommend that the clinical site’s surgical services department consider implementing an 
evidence-based multimodal pain management protocol, and that they consider more options for 
non-narcotic analgesics in PACU. I also recommend they monitor the antiemetic needs and 
explore possible causes if they continue to increase. The program evaluation could be expanded 
to include Phase II recovery room and full years instead of 3-month samples for a more complete 
picture. The evaluation could also be expanded to compare other variables such as service lines 
or anesthetic given, or to include other analgesic medication routes of administration such as 
intra-muscular injections, epidural medications, or rectal medications. Other hospital 
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Appendix A: Demographics for Hennepin County and the State of Minnesota 2018 & 2019 
Note. From County Health Rankings and Roadmaps, by The University of Wisconsin Population Health Institute, 2019 








State of MN 
2018 
State of MN 
2019 
Population 1,232,483 1,252,024 5,519,952 5,576,606 
% below 18 years of age 22% 22% 23% 23.30% 
% 65 and older 13.20% 13.60% 15.10% 15.40% 
% Non-Hispanic African 
American 12.70% 13.10% 6.00% 6.30% 
% American Indian and 
Alaskan Native 1.10% 1.10% 1.30% 1.40% 
% Asian 7.40% 7.60% 4.90% 5.10% 
% Native Hawaiian/Other 
Pacific Islander 0.10% 0.10% 0.10% 0.10% 
% Hispanic 6.90% 7% 5% 5.40% 
% Non-Hispanic white 69.60% 68.90% 80.60% 79.90% 
% not proficient in English 4% 3% 2% 2% 
% Females 50.60% 50.50% 50.20% 50.20% 
% Rural 2.20% 2.20% 26.70% 26.70% 
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major surgery; 60 
trials ranging 
from n=20 to 514 
24-hour morphine 
consumption when 
paracetamol, NSAID, or 
COX-2 inhibitors are given 
in addition to morphine PCA 
 
Decrease in 24 h morphine consumption when 
paracetamol, NSAID, or COX-2 inhibitors are given in 
addition to PCA morphine after surgery, with no clear 
difference between them. 
 
When paracetamol, NSAIDs, or COX-2 inhibitors were 
added to patient-controlled analgesia (PCA) morphine, 
there was a statistically significant reduction in 
morphine consumption. 
Did not account for any synergistic effects 
between the non-opioid analgesics and 
morphine. 
 
Did not take into consideration any effect 
differences between the 3 non-opioids at 









N/A N/A Multimodal perioperative protocol and postoperative 
protocol for painful surgeries where regional anesthesia 
is not utilized.  
Some of the recommendations made were 
based on lower quality studies and were 
presented as something to consider in 
patient care rather than a practice standard 
to follow. 
4A 






adult patients in 
the 
acetaminophen 
groups and 331 




operative pain scores, 
gastrointestinal events 
(nausea, vomiting). 
Intravenous acetaminophen was efficacious for 
reducing postoperative pain and opioid consumption 
than the placebo following total joint arthroplasty. 
A limited number of studies were 
available, and they were of moderate to 
low quality. More RCTs are needed. 
1B 















Primary outcome: number of 
participants achieving at least 
50% pain relief for the 
treatment groups (200mg 
celecoxib, 400mg celecoxib, 
and placebo). 
Secondary outcomes: Use of 
rescue medications within 24 
hours of surgery, median 
time to rescue medications, 
adverse events, withdrawals 
from study 
Celecoxib at its recommended dosage of 400 mg for 
acute pain is an effective analgesic, equivalent to 
ibuprofen 400 mg, but providing a longer duration of 
pain relief than many traditional NSAIDs. 
The studies mainly involved dental surgery 
patients, or dental and orthopedic surgery 
patients. 
1A 
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15 years) with 
established 
postoperative 







Primary outcome:  
Participants achieving at least 
50% of maximum pain relief 
over four to six hours for the 
treatment groups (placebo, 
ibuprofen, or ibuprofen + 
paracetamol). 
Secondary outcomes: Median 
(or mean) time to use of 
rescue medication; Number 
of participants using rescue 
medication; Number of 
participants with: any 
adverse event; any serious 
adverse event (as reported in 
the study); withdrawal due to 
an adverse event; Other 
withdrawals: withdrawals for 
reasons other than lack of 
efficacy (participants using 
rescue medication.) 
Fewer participants required rescue medication with the 
ibuprofen + paracetamol combination than with placebo 
or ibuprofen alone. 
 
Ibuprofen plus paracetamol combinations provided 
better analgesia than either drug alone (at the same 
dose), with a smaller chance of needing additional 
analgesia over about eight hours, and with a smaller 
chance of experiencing an adverse event. 
 
 
The studies used involved dental surgery 
patients. There were only 3 studies 
included in the review. 
1A 










Primary outcome: Number of 
participants achieving at least 
50% pain relief over 4 to 6 
hours. Secondary outcomes:  
Numbers of participants 
using rescue medication over 
specified time periods, time 
to use of rescue medication, 
adverse events, and 
withdrawal from studies. 
A single dose of ibuprofen 400mg is an effective 
analgesic, providing at least 50% pain relief to over half 
of the treated patients with acute, moderate to severe, 
postoperative pain. 
The study is older (2009). Only one 
treatment arm utilized doses of 800mg 
ibuprofen. Most of the studies were on 
dental surgery patients. 
1A 


























any kind of 
surgery, 
including dental, 
who were able to 
self-report pain 
intensity or pain 
relief. 
Primary outcomes 
1. Pain relief: number of 
participants experiencing at 
least 50% of maximum pain 
relief over four or six hours 
postintervention. 2. Pain 
intensity: mean pain intensity 
over both the four- and six-
hour postintervention periods 
in each treatment arm and 
their corresponding standard 
deviations (SD), and in turn 
calculated the mean pain 
difference between groups.  
Secondary outcomes 
Time to achieve 50% pain 
relief, number of participants 
requiring rescue medication 
during the four to six hours 
after administration of the 
study drugs, mean time to 
requiring rescue medication, 
opioid consumption, patient 
satisfaction, adverse events, 
withdrawals. 
IV paracetamol and IV propacetamol are statistically 
superior to placebo for the outcome of the proportion of 
participants achieving at least 50% pain relief over four 
or six hours. 
 
Neither IV paracetamol nor IV propacetamol were 
clinically superior for any efficacy outcome versus 
other analgesic agents, such as nonsteroidal anti-
inflammatory drugs (NSAIDs) or opioids. Both offer an 
advantage over oral paracetamol due to their faster 
onset of action and in that many patients are unable to 
tolerate oral medication post-surgically. 
Only one of the 75 studies had at least 200 
participants in each study arm. Some non-
















pain taking oral 
analgesics. 
The overall objective was to 
provide an overview of 
adverse event rates 
associated with single dose 
oral analgesics, compared 
with placebo, for acute 
postoperative pain in adults. 
 
Adverse events, serious 
adverse events (including 
death), and specific adverse 
events for the drugs being 
compared (NSAIDs, NSAIDs 
given in combination with 
non-opioid drugs, 
paracetamol, opioids or 
opioid combination drugs). 
Serious adverse events were rare, occurring a rate of 
about 1 in 3200 participants. 
 
For several opioids and opioid combinations, the event 
rate with active drug was significantly higher than with 
placebo. For most comparisons, there was no 
statistically significant difference between NSAID and 
placebo. For 
ibuprofen200mgplusparacetamol500mgandforibuprofen 
400 mg plus paracetamol 1000 mg, the adverse event 
rate with the combination was lower than with placebo. 
For ibuprofen 200 mg plus caffeine 100 mg, the 
adverse event rate with the combination was 
statistically higher than with placebo.  There was no 
statistically significant difference between paracetamol 
and placebo for any comparison. There was no 
difference between gabapentin and placebo. 
Most participants were younger adults who 
had dental surgery (molar extraction). 
5A 





















460 studies and 
50,000 
participants); 




pain in adults 
(aged 15 years 
or greater). 
The overall objective was to 
summarize the efficacy of 
pharmaceutical interventions 
for acute pain in adults with 
at least moderate pain 
following surgery who have 
been given a single dose of 
oral analgesic. 
 
Drugs for which Cochrane 
reviews found no 
information, drugs for which 
Cochrane reviews found 
inadequate information 
(fewer than 200 participants 
in comparisons in two 
studies), drugs for which 
Cochrane reviews found no 
evidence of effect or 
evidence of no effect, pairs 
of drug and dose for which 
Cochrane reviews found 
evidence of effect, but where 
results were potentially 
subject to publication bias, 
pairs of drug and dose for 
which Cochrane reviews 
found evidence of effect, 
where results were reliable 
and not subject to potential 
publication bias, percentage 
of participants achieving 
target of at least 50% 
maximum pain relief, time to 
re-medication, percentage re-
medicating. 
Long duration of action (eight hours or greater) was 
found for etoricoxib 120 mg, diflunisal 500 mg, 
paracetamol 650 mg plus oxycodone 10 mg, naproxen 
500/550 mg, celecoxib 400 mg, and ibuprofen 400 mg 
plus paracetamol 1000 mg. 
 
Fast acting formulations and fixed dose combinations of 
analgesics can produce good and often long-lasting 
analgesia at relatively low doses. 
Most of the studies involved dental surgery 
patients. 
5A 
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N/A  Multimodal pain management protocol. Some of the recommendations made were 
based on lower quality studies and were 
presented as something to consider in 




Note: Adapted from “Lessons from Practice: Using the JHNEBP Tools” by D. Dang & S.L. Dearholt, Johns Hopkins Nursing Evidence-Based Practice: Model 
and Guidelines (3rd ed., p.253), 2018, Sigma Theta Tau International. Copyright 2018 by Sigma Theta Tau International.  
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Appendix C: Revised Pain Medication Administration Guidelines Logic Model
Inputs Activities Outputs Outcomes 
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medications will 
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Appendix D: Letter of Introduction and PACU Nurse Survey 
Dear fellow nurses, 
I am a doctoral nursing student completing my Doctor of Nursing Practice degree through Duquesne 
University School of Nursing in Pittsburgh (online program). I am working with your PACU manager, Chris 
Kraulik, on a project to complete my doctoral requirements.  
The PACU order sets were changed in March of 2017 to include more clear guidance for pain 
medication administration. I am evaluating patient satisfaction scores and data on length-of-stay, admission 
and discharge pain scores, pain medications and antiemetic medications given in PACU and their costs, and 
PACU holds before the change (April, May, June 2016 and October, November, December 2016) and after the 
change (April, May, June of 2017, 2018, & 2019; January, February, March of 2020).  
In addition to evaluating data from around 15,000 cases, I need your input regarding your perceptions 
of the utility and impact of the guidelines on your practice and on patient outcomes. I created a survey with 
some Likert scale questions for you to answer, as well as a few open-ended questions. Your survey answers 
and input, along with the data from EPIC, will allow for a comprehensive evaluation of the change and may 
lead to the discovery of other quality improvement opportunities in PACU. Your participation and opinions are 
important for the success of the project, so please complete the survey. Your co-worker, Luanna Flaaen, has 
graciously offered to help me distribute the survey to you all. I live in Minneapolis, but because of the 
pandemic, I am not allowed to come to North Memorial myself. With your help, I will be able to complete my 
degree by the end of spring semester 2021. Thank you in advance for completing the survey and being candid 
in your responses. 
Sincerely, 
Elizabeth (Liz) Gerber 
DNP student, CRNA, RN 
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March 1, 2017 the pain medication order sets were updated for PACU. A significant focus of that 
update included revising the guidelines for IV pain medication administration to the following: 
 
Fentanyl 25-50mcg IV every 5 minutes as needed for acute surgical pain up to 200mcg while in recovery 
area 
 
Dilaudid 1mg/1mL syringe 0.2-0.4mg IV every 5 minutes as needed for 5 doses for post-acute pain 
management while in recovery area. 
 
In this survey, the terms “guidelines”, “revised pain medication guidelines”, “revised guidelines”, and 
“pain medication guidelines” refer to the pain medication order sets used from March 1, 2017 to 
present. 
1. I worked as a PACU nurse at North 
Memorial before March 1, 2017. 
Circle one answer: 
 
Yes  
No (If no, skip to question #12) 
2. I treated post-operative 
pain differently after the 
revised pain medication 
guidelines were implemented. 
 
 
3. Using the guidelines 
improved patient care. 
 
 
4. Patients seemed more 
satisfied when I treated their 
pain using the guidelines. 
  
5. I gave less IV fentanyl to 




6. Using the guidelines 
improved patient comfort. 
 
 
7. I gave more IV dilaudid to 
patients after the guidelines 
were implemented. 
  
8. I changed the way I treated 
postoperative pain because of 
the revised pain medication 
guidelines.  
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9. I gave fewer IV opioid 
medications to patients after 
the guidelines were 
implemented.  
10. I gave more oral pain 
medications in PACU after the 
guidelines were implemented. 
 
11. I gave more non-opioid 
pain medications in PACU 
after the guidelines were 
implemented.  
12. Using the guidelines 
helped me feel more 
confident in treating pain. 
 
13. The pain medication 
guidelines are practical. 
 
14. I utilize the pain 
medication guidelines to help 
me decide which medication 
to administer.  
15. The pain medication 
guidelines are easy to use. 
 
16. How did the guidelines affect your practice?  
17. How did the guidelines affect patient outcomes?  
18. How did the guidelines affect PACU length-of-stay?  
19. What was your perception of the project to change the pain medication guidelines?  
20. Please write anything else you would like to share about your experiences related to the change 
itself (project, process, roll-out, staff education, communication, etc.) and your experiences using 
the pain medication guidelines in patient care. 
 
21. Please share any current opportunities for quality improvement in PACU.  
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Appendix E: Average Charge Per Medication Dose 
Medication Average Charge 
ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION $99.40 
ACETAMINOPHEN 10 MG/ML BOLUS (NEONATE) (PEDS) $105.08 
ACETAMINOPHEN 325 MG TABLET $4.22 
ACETAMINOPHEN 325 MG/10.15 ML ORAL SUSPENSION $0.24 
ACETAMINOPHEN 500 MG TABLET $9.49 
ASPIRIN 325 MG TABLET $0.25 
BUTALBITAL-ASPIRIN-CAFFEINE 50 MG-325 MG-40 MG CAPSULE $2.84 
FENTANYL (PF) 100 MCG/2 ML (50 MCG/ML) INTRAVENOUS SYRINGE $86.04 
FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION $40.49 
HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET $21.05 
HYDROMORPHONE (PF) 2 MG/ML INJECTION SYRINGE WRAPPER $40.40 
HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE $40.35 
HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE WRAPPER $42.91 
HYDROMORPHONE 1 MG / 1 ML ORAL SYRINGE $25.11 
HYDROMORPHONE 1 MG/1 ML INJECTION SYRINGE WRAPPER $41.56 
HYDROMORPHONE 1 MG/ML INJECTION SYRINGE $41.25 
HYDROMORPHONE 2 MG TABLET $15.39 
HYDROMORPHONE 2 MG/ML INJECTION SYRINGE $39.16 
HYDROMORPHONE 4 MG TABLET $21.11 
KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION $43.29 
MEPERIDINE (PF) 25 MG/ML INJECTION $42.30 
MEPERIDINE (PF) 25 MG/ML INJECTION SYRINGE $44.02 
METHADONE 10 MG TABLET $21.07 
METHADONE 10 MG/ML ORAL CONCENTRATE $2.11 
MORPHINE 1-4 MG IV SOLUTION $32.05 
MORPHINE 2 MG/ML INJECTION WRAPPER $44.13 
MORPHINE 2-4 MG IV SOLUTION $44.08 
MORPHINE ER 30 MG TABLET,EXTENDED RELEASE $20.30 
MORPHINE ER 60 MG TABLET,EXTENDED RELEASE $28.12 
NALBUPHINE 20 MG/ML INJECTION SOLUTION $49.53 
ONDANSETRON 4 MG DISINTEGRATING TABLET $20.92 
ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION $40.58 
OXYCODONE 5 MG TABLET $8.75 
OXYCODONE 5 MG/5 ML ORAL SOLUTION $17.96 
OXYCODONE ER 20 MG TABLET,CRUSH RESISTANT,EXTENDED RELEASE 12 HR $25.99 
OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET $20.45 
PROCHLORPERAZINE EDISYLATE 10 MG/2 ML (5 MG/ML) INJECTION SOLUTION $49.68 
SCOPOLAMINE 1 MG OVER 3 DAYS TRANSDERMAL PATCH $52.40 
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Appendix F: Supplemental Details for Figures 
 
Table F1. 






Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474;  
PO+IV group 2016 n=16 and 2017-2020 average n=58
 
Table F2. 
Average PACU Discharge Pain Scores  
Year (s) 
PO Group (8% 
increase)  
IV Group (15% 
increase)  





2016 2.7 3.3 4.4 3.3 
2017-2020 2.9 3.8 4.2 3.7 
 
Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474;  
PO+IV group 2016 n=16 and 2017-2020 average n=58.  Scores are on a 0-10 pain scale.
 
Table F3. 











3 groups combined 68% increase 
($310.50) 
2016 $0.00  $458.22  $0.00  $458.22  
2017-2020 $107.36  $633.87  $108.22  $768.72  
 
Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474;  
PO+IV group 2016 n=16 and 2017-2020 average n=58 
Year(s) PO Group 27% 
increase (23 
minutes)  
IV Group 9% 
decrease (10 
minutes) 
PO+IV Group 22% 
decrease (34 
minutes)   




2016 83 115 154 116 
2017-2020 105 105 120 107 












Note. PO group 2016 n=10 and 2017-2020 average n=43; IV group 2016 n=497 and 2017-2020 average n=474;  
PO+IV group 2016 n=16 and 2017-2020 average n=58 
 
Table F5.  
Costs by Analgesic Type and Route of Administration 
 
 
Year(s) PO Group 243% 
increase 
($426.18) 






3 groups combined 2% 
decrease ($1,169.55) 
2016 $175.22  $66,563.67  $2,851.79  $69,635.14  
















Groups combined- PO 
analgesics 238% increase 
($987.67) 
Groups combined- IV 
non-narcotic analgesics 
1% increase ($219.26) 
2016 $69,635.14  $47,871.45 $415.64 $20,443.69 
2017-2020 $68,465.59  $45,420.78 $1,403.31 $20,662.95 
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Appendix G: PO+IV Group Total Analgesic and Antiemetic Costs 
Date Count Medication Average Charge Total cost per med Total cost per year 
2016 1 ACETAMINOPHEN 500 MG TABLET $9.49 $9.49 $2,851.79 
2016 1 ASPIRIN 325 MG TABLET $0.25 $0.25  
2016 1 HYDROMORPHONE 4 MG TABLET $21.11 $21.11  
2016 2 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET $21.05 $42.09  
2016 3 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION $99.40 $298.21  
2016 3 KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION $43.29 $129.87  
2016 4 MEPERIDINE (PF) 25 MG/ML INJECTION SYRINGE $44.02 $176.07  
2016 5 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET $20.45 $102.24  
2016 7 OXYCODONE 5 MG TABLET $8.75 $61.27  
2016 13 FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION $40.49 $526.33  
2016 36 HYDROMORPHONE 1 MG/ML INJECTION SYRINGE $41.25 $1,484.86  
2017 3 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION $99.40 $298.21 $5,004.15 
2017 3 ACETAMINOPHEN 325 MG TABLET $4.22 $12.65  
2017 4 ACETAMINOPHEN 500 MG TABLET $9.49 $37.95  
2017 4 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET $21.05 $84.19  
2017 4 MEPERIDINE (PF) 25 MG/ML INJECTION SYRINGE $44.02 $176.07  
2017 5 KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION $43.29 $216.45  
2017 6 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET $20.45 $122.69  
2017 13 OXYCODONE 5 MG TABLET $8.75 $113.79  
2017 23 FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION $40.49 $931.19  
2017 73 HYDROMORPHONE 1 MG/ML INJECTION SYRINGE $41.25 $3,010.97  
2018 1 ACETAMINOPHEN 325 MG TABLET $4.22 $4.22 $3,116.86 
2018 1 HYDROMORPHONE 2 MG TABLET $15.39 $15.39  
2018 1 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION $40.58 $40.58  
2018 2 ACETAMINOPHEN 500 MG TABLET $9.49 $18.98  
2018 4 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION $99.40 $397.62  
2018 4 KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION $43.29 $173.16  
2018 5 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET $21.05 $105.24  
2018 6 HYDROMORPHONE 2 MG/ML INJECTION SYRINGE $39.16 $234.94  
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Date Count Medication Average Charge Total cost per med Total cost per year 
2018 7 OXYCODONE 5 MG TABLET $8.75 $61.27  
2018 10 HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE $40.35 $403.49  
2018 10 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET $20.45 $204.48  
2018 36 FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION $40.49 $1,457.52  
2019 1 HYDROMORPHONE 2 MG TABLET $15.39 $15.39 $15,071.95 
2019 1 METHADONE 10 MG TABLET $21.07 $21.07  
2019 2 MORPHINE 2 MG/ML INJECTION WRAPPER $44.13 $88.25  
2019 5 ACETAMINOPHEN 325 MG TABLET $4.22 $21.08  
2019 5 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION $40.58 $202.91  
2019 6 ACETAMINOPHEN 500 MG TABLET $9.49 $56.93  
2019 8 KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION $43.29 $346.33  
2019 14 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET $21.05 $294.66  
2019 19 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION $99.40 $1,888.68  
2019 28 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET $20.45 $572.53  
2019 42 HYDROMORPHONE 2 MG/ML INJECTION SYRINGE $39.16 $1,644.55  
2019 44 HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE WRAPPER $42.91 $1,887.97  
2019 48 OXYCODONE 5 MG TABLET $8.75 $420.14  
2019 188 FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION $40.49 $7,611.48  
2020 1 HYDROMORPHONE 1 MG / 1 ML ORAL SYRINGE $25.11 $25.11 $12,749.09 
2020 2 MORPHINE 2 MG/ML INJECTION WRAPPER $44.13 $88.25  
2020 2 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION $40.58 $81.16  
2020 3 MEPERIDINE (PF) 25 MG/ML INJECTION $42.30 $126.90  
2020 5 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET $21.05 $105.24  
2020 8 KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION $43.29 $346.33  
2020 11 ACETAMINOPHEN 500 MG TABLET $9.49 $104.36  
2020 12 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET $20.45 $245.37  
2020 13 ACETAMINOPHEN 325 MG TABLET $4.22 $54.81  
2020 16 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION $99.40 $1,590.46  
2020 22 HYDROMORPHONE (PF) 2 MG/ML INJECTION SYRINGE WRAPPER $40.40 $888.77  
2020 56 OXYCODONE 5 MG TABLET $8.75 $490.16  
2020 58 HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE WRAPPER $42.91 $2,488.69  
2020 151 FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION $40.49 $6,113.47  
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Appendix H: IV Group Total Analgesic and Antiemetic Costs 
Date Count Medication Average Charge Total cost per med Total cost per year 
2016 1 SCOPOLAMINE 1 MG OVER 3 DAYS TRANSDERMAL PATCH $52.40 $52.40 $67,021.89 
2016 10 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION $40.58 $405.81  
2016 13 HYDROMORPHONE 10 MG/50 ML PCA IV INFUSION (PREMIX) $69.57 $904.36  
2016 40 MEPERIDINE (PF) 25 MG/ML INJECTION SYRINGE $44.02 $1,760.73  
2016 72 KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION $43.29 $3,116.93  
2016 170 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION $99.40 $16,898.67  
2016 221 FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION $40.49 $8,947.54  
2016 847 HYDROMORPHONE 1 MG/ML INJECTION SYRINGE $41.25 $34,935.44  
2017 1 MORPHINE 50 MG/50 ML PCA IN 0.9 % SODIUM CHLORIDE IV (PREMIX) $71.00 $71.00 $72,854.47 
2017 1 SCOPOLAMINE 1 MG OVER 3 DAYS TRANSDERMAL PATCH $52.40 $52.40  
2017 2 NALBUPHINE 20 MG/ML INJECTION SOLUTION $49.53 $99.07  
2017 3 MORPHINE 2-4 MG IV SOLUTION $44.08 $132.23  
2017 5 HYDROMORPHONE 10 MG/50 ML PCA IV INFUSION (PREMIX) $69.57 $347.83  
2017 15 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION $40.58 $608.72  
2017 39 MEPERIDINE (PF) 25 MG/ML INJECTION SYRINGE $44.02 $1,716.71  
2017 78 KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION $43.29 $3,376.67  
2017 187 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION $99.40 $18,588.54  
2017 305 FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION $40.49 $12,348.41  
2017 861 HYDROMORPHONE 1 MG/ML INJECTION SYRINGE $41.25 $35,512.89  
2018 1 ACETAMINOPHEN 10 MG/ML BOLUS (NEONATE) (PEDS) $105.08 $105.08 $48,449.84 
2018 1 FENTANYL (PF) 2,500 MCG/50 ML PCA IV (PREMIX) $173.26 $173.26  
2018 1 ONDANSETRON 4 MG DISINTEGRATING TABLET $20.92 $20.92  
2018 2 MORPHINE 50 MG/50 ML PCA IN 0.9 % SODIUM CHLORIDE IV (PREMIX) $71.00 $142.00  
2018 2 PROCHLORPERAZINE EDISYLATE 10 MG/2 ML (5 MG/ML) INJECTION SOLUTION $49.68 $99.36  
2018 6 HYDROMORPHONE 10 MG/50 ML PCA IV INFUSION (PREMIX) $69.57 $417.40  
2018 13 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION $40.58 $527.56  
2018 15 HYDROMORPHONE 10 MG/50 ML PCA IV INFUSION (MIXTURE) $142.35 $2,135.19  
2018 26 MEPERIDINE (PF) 25 MG/ML INJECTION $42.30 $1,099.76  
2018 38 HYDROMORPHONE 2 MG/ML INJECTION SYRINGE $39.16 $1,487.93  
2018 187 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION $99.40 $18,588.54  
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Date Count Medication Average Charge Total cost per med Total cost per year 
2018 231 HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE $40.35 $9,320.59  
2018 354 FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION $40.49 $14,332.25  
2019 1 ACETAMINOPHEN 10 MG/ML BOLUS (NEONATE) (PEDS) $105.08 $105.08 $67,985.45 
2019 1 MORPHINE 50 MG/50 ML PCA IN 0.9 % SODIUM CHLORIDE IV (PREMIX) $71.00 $71.00  
2019 1 NALBUPHINE 20 MG/ML INJECTION SOLUTION $49.53 $49.53  
2019 1 PROCHLORPERAZINE EDISYLATE 10 MG/2 ML (5 MG/ML) INJECTION SOLUTION $49.68 $49.68  
2019 2 MORPHINE 2 MG/ML INJECTION WRAPPER $44.13 $88.25  
2019 4 HYDROMORPHONE 10 MG/50 ML PCA IV INFUSION (PREMIX) $69.57 $278.27  
2019 23 MEPERIDINE (PF) 25 MG/ML INJECTION $42.30 $972.87  
2019 26 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION $40.58 $1,055.11  
2019 28 HYDROMORPHONE (PF) 2 MG/ML INJECTION SYRINGE WRAPPER $40.40 $1,131.17  
2019 60 KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION $43.29 $2,597.44  
2019 142 HYDROMORPHONE 2 MG/ML INJECTION SYRINGE $39.16 $5,560.15  
2019 177 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION $99.40 $17,594.50  
2019 205 HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE WRAPPER $42.91 $8,796.22  
2019 732 FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION $40.49 $29,636.18  
2020 2 MORPHINE 2 MG/ML INJECTION WRAPPER $44.13 $88.25 $46,680.21 
2020 3 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION $40.58 $121.74  
2020 4 HYDROMORPHONE 10 MG/50 ML PCA IV INFUSION (PREMIX) $69.57 $278.27  
2020 5 HYDROMORPHONE 1 MG/1 ML INJECTION SYRINGE WRAPPER $41.56 $207.78  
2020 22 MEPERIDINE (PF) 25 MG/ML INJECTION $42.30 $930.57  
2020 30 HYDROMORPHONE (PF) 2 MG/ML INJECTION SYRINGE WRAPPER $40.40 $1,211.96  
2020 33 KETOROLAC 30 MG/ML (1 ML) INJECTION SOLUTION $43.29 $1,428.59  
2020 124 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION $99.40 $12,326.09  
2020 253 HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE WRAPPER $42.91 $10,855.82  
2020 475 FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION $40.49 $19,231.13  
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Appendix I: PO Group Total Analgesic and Antiemetic Costs 
Date Count Medication Average Charge Total cost per med Total cost per year 
2016 1 ACETAMINOPHEN 325 MG TABLET $4.22 $4.22 $175.22 
2016 1 ACETAMINOPHEN 500 MG TABLET $9.49 $9.49  
2016 1 HYDROMORPHONE 2 MG TABLET $15.39 $15.39  
2016 2 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET $20.45 $40.90  
2016 5 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET $21.05 $105.24  
2017 4 ACETAMINOPHEN 325 MG TABLET $4.22 $16.87 $363.85 
2017 4 ACETAMINOPHEN 500 MG TABLET $9.49 $37.95  
2017 4 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET $21.05 $84.19  
2017 7 OXYCODONE 5 MG TABLET $8.75 $61.27  
2017 8 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET $20.45 $163.58  
2018 1 ASPIRIN 325 MG TABLET $0.25 $0.25 $538.29 
2018 3 ACETAMINOPHEN 325 MG TABLET $4.22 $12.65  
2018 6 ACETAMINOPHEN 500 MG TABLET $9.49 $56.93  
2018 7 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET $21.05 $147.33  
2018 8 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET $20.45 $163.58  
2018 18 OXYCODONE 5 MG TABLET $8.75 $157.55  
2019 1 ACETAMINOPHEN 325 MG/10.15 ML ORAL SUSPENSION $0.24 $0.24 $722.31 
2019 1 BUTALBITAL-ASPIRIN-CAFFEINE 50 MG-325 MG-40 MG CAPSULE $2.84 $2.84  
2019 1 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION $40.58 $40.58  
2019 1 SCOPOLAMINE 1 MG OVER 3 DAYS TRANSDERMAL PATCH $52.40 $52.40  
2019 5 ACETAMINOPHEN 325 MG TABLET $4.22 $21.08  
2019 5 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET $21.05 $105.24  
2019 9 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET $20.45 $184.03  
2019 13 ACETAMINOPHEN 500 MG TABLET $9.49 $123.34  
2019 22 OXYCODONE 5 MG TABLET $8.75 $192.56  
2020 1 ACETAMINOPHEN 325 MG/10.15 ML ORAL SUSPENSION $0.24 $0.24 $995.86 
2020 1 ASPIRIN 325 MG TABLET $0.25 $0.25  
2020 1 HYDROMORPHONE 2 MG TABLET $15.39 $15.39  
2020 1 METHADONE 10 MG TABLET $21.07 $21.07  
2020 1 MORPHINE ER 60 MG TABLET,EXTENDED RELEASE $28.12 $28.12  
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Date Count Medication Average Charge Total cost per med Total cost per year 
2020 1 OXYCODONE 5 MG/5 ML ORAL SOLUTION $17.96 $17.96  
2020 3 ONDANSETRON HCL (PF) 4 MG/2 ML INJECTION SOLUTION $40.58 $121.74  
2020 6 ACETAMINOPHEN 325 MG TABLET $4.22 $25.30  
2020 11 HYDROCODONE 5 MG-ACETAMINOPHEN 325 MG TABLET $21.05 $231.52  
2020 11 OXYCODONE-ACETAMINOPHEN 5 MG-325 MG TABLET $20.45 $224.92  
2020 16 ACETAMINOPHEN 500 MG TABLET $9.49 $151.80  
2020 18 OXYCODONE 5 MG TABLET $8.75 $157.55  
 
USING REVISED PAIN MEDICATION ADMINISTRATION  49 
49 
 
Appendix J: All Groups IV Narcotic Costs Per Year 
 
All Groups IV Narcotics (excludes PCA doses)- Sum of Total cost per year per medication 2016 2017 2018 2019 2020 
      
FENTANYL (PF) 50 MCG/ML INJECTION SOLUTION $9,514.35 $14,372.74 $15,789.77 $37,247.66 $25,344.60 
HYDROMORPHONE (PF) 2 MG/ML INJECTION SYRINGE WRAPPER    $1,131.17 $2,036.11 
HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE   $9,724.08   
HYDROMORPHONE 0.5 MG/0.5 ML INJECTION SYRINGE WRAPPER    $10,046.87 $12,548.50 
HYDROMORPHONE 1 MG/1 ML INJECTION SYRINGE WRAPPER     $206.23 
HYDROMORPHONE 1 MG/ML INJECTION SYRINGE $36,420.30 $38,523.85    
HYDROMORPHONE 2 MG/ML INJECTION SYRINGE   $1,722.86 $7,204.70  
MEPERIDINE (PF) 25 MG/ML INJECTION   $1,144.47 $1,012.42 $1,100.46 
MEPERIDINE (PF) 25 MG/ML INJECTION SYRINGE $1,936.80 $1,892.78    
MORPHINE 2 MG/ML INJECTION WRAPPER    $176.50 $176.50 
MORPHINE 2-4 MG IV SOLUTION  $132.23    
NALBUPHINE 20 MG/ML INJECTION SOLUTION  $99.07  $49.53  
Grand Total $47,871.45 $55,020.67 $28,381.19 $56,868.85 $41,412.40 
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Appendix K: Permission to Reprint Table 
 
 
 
 
 
 
